Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 6, 1999

Primary Completion Date

November 15, 2019

Study Completion Date

December 15, 2019

Conditions
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

busulfan

For those not eligible for total body irradiation: busulfan 4 mg/kg/day orally (1 mg/kg orally every 6 hrs) on Days -9 through -6.

DRUG

cyclophosphamide

Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.

BIOLOGICAL

Stem cell infusion

Infused on Day 0

RADIATION

Total body irradiation

165 cGy morning and evening on days -4 through -1.

Trial Locations (1)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00612716 - Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter